T. Rowe Price Associates’s Aimmune Therapeutics, Inc. AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-5,274,902
| Closed | -$88.1M | – | 2643 |
|
|
2020
Q2 | $88.1M | Buy |
5,274,902
+82,229
| +2% | +$1.37M | 0.01% | 668 |
|
|
2020
Q1 | $74.9M | Sell |
5,192,673
-429,865
| -8% | -$6.2M | 0.01% | 658 |
|
|
2019
Q4 | $188M | Buy |
5,622,538
+310,054
| +6% | +$10.4M | 0.02% | 493 |
|
|
2019
Q3 | $111M | Buy |
5,312,484
+65,880
| +1% | +$1.38M | 0.02% | 605 |
|
|
2019
Q2 | $109M | Buy |
5,246,604
+535,072
| +11% | +$11.1M | 0.02% | 622 |
|
|
2019
Q1 | $105M | Sell |
4,711,532
-60,377
| -1% | -$1.35M | 0.02% | 626 |
|
|
2018
Q4 | $114M | Buy |
4,771,909
+86,452
| +2% | +$2.07M | 0.02% | 571 |
|
|
2018
Q3 | $128M | Buy |
4,685,457
+31,516
| +0.7% | +$860K | 0.02% | 604 |
|
|
2018
Q2 | $125M | Buy |
4,653,941
+161,864
| +4% | +$4.35M | 0.02% | 598 |
|
|
2018
Q1 | $143M | Buy |
4,492,077
+1,977,910
| +79% | +$63M | 0.02% | 552 |
|
|
2017
Q4 | $95.1M | Buy |
2,514,167
+1,136,368
| +82% | +$43M | 0.02% | 661 |
|
|
2017
Q3 | $34.2M | Sell |
1,377,799
-18,600
| -1% | -$461K | 0.01% | 996 |
|
|
2017
Q2 | $28.7M | Buy |
1,396,399
+227,627
| +19% | +$4.68M | 0.01% | 1036 |
|
|
2017
Q1 | $25.4M | Buy |
1,168,772
+82,621
| +8% | +$1.8M | ﹤0.01% | 1060 |
|
|
2016
Q4 | $22.2M | Sell |
1,086,151
-76,379
| -7% | -$1.56M | ﹤0.01% | 1102 |
|
|
2016
Q3 | $17.4M | Buy |
1,162,530
+558,432
| +92% | +$8.38M | ﹤0.01% | 1181 |
|
|
2016
Q2 | $6.54M | Buy |
604,098
+115,700
| +24% | +$1.25M | ﹤0.01% | 1359 |
|
|
2016
Q1 | $6.62M | Sell |
488,398
-2,050
| -0.4% | -$27.8K | ﹤0.01% | 1343 |
|
|
2015
Q4 | $9.05M | Buy |
490,448
+48,810
| +11% | +$901K | ﹤0.01% | 1306 |
|
|
2015
Q3 | $11.2M | Buy |
+441,638
| New | +$11.2M | ﹤0.01% | 1286 |
|